Celularity Inc
CELU3.180USD
+0.060+1.92%
시장 운영 시간 （ET）시세는 15분 지연됩니다
71.70M시가총액
손실P/E TTM
자세한 내용은 Celularity Inc 회사
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
회사 정보
종목 코드 CELU
회사 이름Celularity Inc
상장일May 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
직원 수123
유형Ordinary Share
회계 연도 종료May 23
주소170 Park Ave
도시FLORHAM PARK
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호07932
전화19087682170
웹사이트https://celularity.com/
종목 코드 CELU
상장일May 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.85M
+0.12%
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Vincent Levien
Mr. Vincent Levien
Director
Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.85M
+0.12%
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
주주
주주 유형
주주
주주
비율
Genting Bhd
26.45%
Hariri (Robert J)
11.92%
Starr International Company, Inc.
6.38%
Celgene Corporation
4.99%
Lung Biotechnology Inc
3.33%
Other
46.93%
주주
주주
비율
Genting Bhd
26.45%
Hariri (Robert J)
11.92%
Starr International Company, Inc.
6.38%
Celgene Corporation
4.99%
Lung Biotechnology Inc
3.33%
Other
46.93%
주주 유형
주주
비율
Corporation
36.88%
Individual Investor
14.45%
Investment Advisor
9.43%
Insurance Company
3.19%
Investment Advisor/Hedge Fund
1.17%
Hedge Fund
0.35%
Research Firm
0.30%
Bank and Trust
0.20%
Venture Capital
0.04%
Other
33.99%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
104
15.81M
66.01%
-1.35M
2025Q1
140
16.18M
70.80%
+52.81K
2024Q4
156
14.05M
63.43%
-1.62M
2024Q3
169
14.41M
66.16%
-2.07M
2024Q2
181
15.12M
69.86%
-663.91K
2024Q1
187
14.36M
66.56%
-1.48M
2023Q4
186
12.31M
65.02%
-347.56K
2023Q3
186
12.52M
68.51%
+23.28K
2023Q2
200
12.33M
70.15%
-1.64M
2023Q1
224
13.36M
90.76%
-717.66K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Genting Bhd
6.34M
26.45%
--
--
May 15, 2025
Hariri (Robert J)
2.85M
11.92%
+3.28K
+0.12%
May 15, 2025
Starr International Company, Inc.
1.53M
6.38%
--
--
May 15, 2025
Celgene Corporation
1.20M
4.99%
--
--
Feb 07, 2025
Lung Biotechnology Inc
796.88K
3.33%
--
--
Dec 31, 2023
C.V. Starr & Co., Inc.
764.07K
3.19%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
500.13K
2.09%
--
--
Mar 31, 2025
Kehler (Dean C)
281.94K
1.18%
--
--
Feb 07, 2025
Geode Capital Management, L.L.C.
136.04K
0.57%
+4.53K
+3.45%
Mar 31, 2025
Diamandis (Peter)
134.31K
0.56%
-63.82K
-32.21%
May 15, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
비율0%
iShares Micro-Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
날짜
유형
비율
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
